Ignite Creation Date:
2024-05-06 @ 3:23 AM
Last Modification Date:
2024-10-26 @ 11:32 AM
Study NCT ID:
NCT02271139
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2017-03-09
First Post:
2014-10-17
Brief Title:
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase ALK-Rearranged Non-Small Cell Lung Cancer NSCLC After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
None
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2014-10-17
First Submit QC Date:
October 20 2014
Study First Post Date:
2014-10-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-03-07
Last Update Post Date:
2017-03-09
Last Update Post Date Type:
ACTUAL